| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (NCT06025214) | Respirent Pharmaceuticals Co Ltd. | 2023-08-22 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (NCT05982990) | Respirent Pharmaceuticals Co Ltd. | 2023-08-01 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers (NCT05697003) | Respirent Pharmaceuticals Co Ltd. | 2023-02-17 |
| Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (NCT05664061) | Respirent Pharmaceuticals Co Ltd. | 2023-01-30 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions (NCT05397834) | Respirent Pharmaceuticals Co Ltd. | 2022-05-11 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers (NCT05085587) | Respirent Pharmaceuticals Co Ltd. | 2021-10-01 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions (NCT05021887) | Respirent Pharmaceuticals Co Ltd. | 2021-08-13 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers (NCT04746040) | Respirent Pharmaceuticals Co Ltd. | 2021-01-18 |
| A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (NCT04665895) | Respirent Pharmaceuticals Co Ltd. | 2020-12-09 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers (NCT04564456) | Respirent Pharmaceuticals Co Ltd. | 2020-09-22 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers (NCT04546256) | Respirent Pharmaceuticals Co Ltd. | 2020-09-01 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers (NCT04462822) | Respirent Pharmaceuticals Co Ltd. | 2020-08-24 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers (NCT04466176) | Respirent Pharmaceuticals Co Ltd. | 2020-07-01 |
| A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (NCT04124094) | Respirent Pharmaceuticals Co Ltd. | 2019-10-01 |
| Pooled Analysis FP_SX_250_50 (NCT04790838) | Respirent Pharmaceuticals Co Ltd. | 2019-06-02 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers (NCT03975166) | Respirent Pharmaceuticals Co Ltd. | 2019-05-21 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC) (NCT03894280) | Respirent Pharmaceuticals Co Ltd. | 2019-03-12 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers (NCT03820180) | Respirent Pharmaceuticals Co Ltd. | 2019-01-23 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (NCT03751202) | Respirent Pharmaceuticals Co Ltd. | 2018-11-20 |
| A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (NCT03676413) | Respirent Pharmaceuticals Co Ltd. | 2018-10-02 |